Myalepta

Active substance

Metreleptine

Holder

Amryt Pharmaceuticals DAC

Statut

Running

Indication

as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients:
-    with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and above
-    with confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.

Public documents

Approbation

Approbation amendment

Information for the patient

Information for the patient - amendment

Informed consent

Last update

26/06/2025